P1740: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING‐ADJUSTED... von Shah, N., Ayers, D., Cope, S., Karampampa, K., Towle, K., Braverman, J., Mojebi, A., Caisip, C., Dhanda, D.

Volltext

CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Ref... von Towle, K., Caisip, C., Karampampa, K., Cope, S., Dhanda, D.

Volltext

PCR209 Joint Modeling of Progression-Free Survival (PFS) and Patient-Reported Symptoms Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients von Knop, S, Einsele, H, Dhanda, D, Marshall, T, Eliason, L, McLoone, D, Caisip, C, Chen, J, Boehm, D, Dhamane, AD, Ramasamy, K, Cope, S, Towle, K

Volltext

EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy von Paul, E, LaFontaine, PR, Xu, Y, Inocencio, TJ, Atsou, K, D'Avella, MC, Ader, J, Guyot, P, Caisip, C, Quon, P, Chen, CI, Cope, S

Volltext